Latest Financial Performance News

Cleo Diagnostics reported a $4 million loss for FY2025 while making significant strides toward FDA approval of its novel ovarian cancer blood test. The company is progressing clinical trials and scaling manufacturing in preparation for market entry.

Race Oncology Limited reported a significantly reduced loss for FY2025, driven by key clinical trial progress and strategic leadership changes. The company advances its RC220 program with promising Phase 1 dosing milestones and strengthens its governance to support future growth.

Ironbark Capital Limited reported a 17.6% increase in net profit for FY2025, driven by higher investment income and realised gains, alongside a raised fully franked dividend and an extended share buy-back program.

Eildon Capital Group reported a $5.7 million net loss in FY25, weighed down by $8 million in one-off charges, while simplifying its portfolio and entering a new joint venture in North Queensland.

Eildon Capital Group reported a net loss of $5.7 million for FY2025, weighed down by significant one-off impairments, while pivoting to focused real estate investments with a new $20.8 million joint venture in Queensland.

Wagners Holding Company Limited reported a solid FY25 with revenue of $431.3 million, driven by growth in construction materials and composite fibre technologies, while reducing net debt by 29%.

WCM Global Growth Limited reported a robust FY2025 with a 31% portfolio return and raised its fully franked final dividend, alongside an upgraded progressive dividend policy and a shareholder-friendly DRP discount.

WCM Global Growth Limited reported a robust 53% rise in net profit for FY2025, driven by strong portfolio returns and a successful capital raise, prompting an increased final dividend and upward revision of future dividends.

Australis Oil & Gas reported a reduced half-year loss and positive cash flow despite lower production, while actively seeking a development partner for its Tuscaloosa Marine Shale assets.

Star Combo Pharma has reported a remarkable jump in profit for FY2025, driven by strong revenue growth and a settled insurance claim, while declaring its second dividend and planning production expansion.

Star Combo Pharma Limited reported a 7% increase in total revenue to $27.8 million for FY25, propelled by a 10% rise in its core OEM and Own Brands segment. The company’s profit before tax surged to $5.31 million, reflecting operational strength despite challenges in its Retail division.

Hazer Group has reported a remarkable FY25 performance with revenues more than doubling and losses slashed by 60%, underpinned by a strategic partnership with KBR and early commercial revenues.